Clinical Trial Update: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study examining predictors of response to the combination of pembrolizumab and olaparib in patients with unresect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Institut fuer Frauengesundheit | Conditions: Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING